Caraccio N, Monzani F, Casolaro A, Pucci E, Luisi M, Franchi F
Clinica Medica II, Università, Pisa.
Recenti Prog Med. 1995 Jun;86(6):226-30.
Synthetic TRH (TRH-T) has recently been used for the treatment of chronic and acute neurologic disorders. We studied the effects of long-term (30 days) refracted daily intramuscular administration of 4 mg TRH-T on neuroendocrine and cardiovascular system and on glucose and fat metabolism in 22 patients (mean age 62.7 +/- 10.9) with chronic cerebrovascular disease. All subjects were submitted to ECG and arterial blood pressure determination and were assayed for TSH, thyroid hormone, PRL, glucose, creatinine, nitrogen, glutamine transaminase, cholesterol and triglycerides plasma levels before therapy (T0), after 30 treatment days (T30) and after a 15 days washout (T45). Thyroid hormone, TSH and PRL serum levels were detected also after 15 days of TRH-T therapy (T15). In addition, TSH and PRL response to 200 micrograms iv TRH was assessed at T0, T30 and T45. TRH-T administration did not cause significant alterations of neuroendocrine balance. Furthermore, we observed no changes in lipid metabolism, renal and liver function, arterial blood pressure, and ECG. In conclusion, TRH-T may be safely used in elderly patients with chronic cerebrovascular disease, independently to cardiovascular disorders.
合成促甲状腺激素释放激素(TRH-T)最近已被用于治疗慢性和急性神经系统疾病。我们研究了22例(平均年龄62.7±10.9岁)慢性脑血管疾病患者长期(30天)每日肌肉注射4毫克TRH-T对神经内分泌和心血管系统以及对葡萄糖和脂肪代谢的影响。所有受试者在治疗前(T0)、治疗30天后(T30)和停药15天后(T45)均接受心电图和动脉血压测定,并检测促甲状腺激素、甲状腺激素、催乳素、葡萄糖、肌酐、氮、谷氨酰胺转氨酶、胆固醇和甘油三酯的血浆水平。在TRH-T治疗15天后(T15)也检测甲状腺激素、促甲状腺激素和催乳素的血清水平。此外,在T0、T30和T45评估促甲状腺激素和催乳素对静脉注射200微克TRH的反应。TRH-T给药未引起神经内分泌平衡的显著改变。此外,我们未观察到脂质代谢、肾功能和肝功能、动脉血压及心电图的变化。总之,TRH-T可安全用于患有慢性脑血管疾病的老年患者,与心血管疾病无关。